Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

General Health

Health

FDA

Clinical Trials

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

More Like This

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance

Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)

Biocytogen Announces ADC Innovator Tubulis Has Signed Global Exclusive License Agreement for Single Antibody

Business Wire associated0

Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator